Spironolactone
General properties
Essential hypertension
Spironolactone should be prescribed together with other antihypertensive agents when conventional agents are ineffective or cause undesirable effects.
Hypertension
In case of increased aldosterone secretion, hypokalemia and metabolic alkalosis.
Edema in heart failure
Especially in patients receiving digitalis therapy and in patients at risk of hypokalemia caused by diuretics.
Cirrhosis with ascites
This condition is often associated with very high aldosterone levels.
Nephrotic syndrome
When conventional measures such as water and salt restriction and conventional diuretic therapy do not make a desired effect.
Idiopathic edema
In the case of secondary aldosteronism.
Primary hyperaldosteronism
Diagnosis and therapy.
• acute renal failure;
• severe renal failure (creatinine clearance < 30 ml/min);
• anuria;
• Addison’s disease;
• hyperkalemia;
• hyponatremia;
• simultaneous use of eplerenone;
• hypersensitivity to spironolactone or to any excipient included in the medicinal product;
• pregnancy or breastfeeding.
Pharmaceutical characteristics
25 mg and 100 mg tablets: film-coated tablets, pale yellow to yellow, straight solid cylinders, with convex end surfaces;
50 mg tablets: film-coated tablets, white or off-white, straight solid cylinders, with convex end surfaces.
Store in the original packaging at temperature not exceeding 30 °C. Keep out of reach of children.
